Waisman Biomanufacturing

Development and Analytical Services

Stability and Comparability

Regulators and service providers expect stability data to support toxicology and human clinical studies. Waisman offers custom, customer-tailored stability to meet regulatory and budget requirements:

  • ICH or customized timepoints
  • Product-appropriate stability indicating or characterization methods from the same lab as release testing; i.e. no QC method transfer required to support stability testing
  • Real-time, accelerated, and in-use testing scenarios (freeze-thaw, formulation or device compatibility, shipping studies)
  • Support for pilot batch stability, engineering batch stability, Drug Product, Drug Substance, and/or intermediate testing and characterization

Comparability Testing

Waisman also recognizes that changes occur during lengthy product development. We offer custom comparability testing in scenarios including, but not limited to, the following:

  • Container closure changes
  • Process changes due to further development
  • Cell bank changes (e.g. MCB to 2-tiered M/WCB)
  • Manufacturing process changes from incoming tech transfer, internal scale up, or to support transfer out of Waisman for further development
  • Other custom scenarios